Prognosis: Breakthrough

Learning to Love Big Pharma

Prognosis: Breakthrough

Gilead Sciences announced today that it will charge the U.S. government and other developed countries $390 per vial for its coronavirus-fighting drug remdesivir. That begins to answer a big question as drug companies race to find treatments and develop vaccines for the virus: How much will it cost us? But Riley Griffin and Emma Court report that the Pharmaceutical industry is hoping Covid-19 will give it a chance to rebrand; and get the focus off drug prices. Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

Next Episodes

Prognosis: Breakthrough

Keeping Elderly Patients Safe @ Prognosis: Breakthrough

📆 2020-06-26 22:21 / 00:15:44


Prognosis: Breakthrough

What Happened in Houston @ Prognosis: Breakthrough

📆 2020-06-25 23:33 / 00:16:07



Prognosis: Breakthrough

The Next Two Years of the Virus @ Prognosis: Breakthrough

📆 2020-06-23 23:03 / 00:16:00